AbbVie strikes $1.19 billion collaboration deal with Halozyme, Ferring Pharmaceuticals expands into Russian market & more – 5 GI/endoscopy company key notes

Written by Carrie Pallardy | June 03, 2015 | Print  |

Here are five recent news updates on gastroenterology and endoscopy companies.

AbbVie and Halozyme Therapeutics reached a global collaboration agreement that could be worth $1.19 billion, according to a report by The Wall Street Journal

Ferring Pharmaceuticals awarded an agreement with Russian pharmaceutical company NovaMedica, which allows NovaMedica to commercialize a number of Ferring's inflammatory bowel disease products in the Russian market.

Medigus was awarded an additional supply order of its micro ScoutCam technology from the National Aeronautics and Space Administration. The technology will be used in NASA's Robotic Refueling Mission.

Synthetics Biologics added Klaus Gottlieb, MD, FACG, to its team as vice president of clinical and regulatory affairs. Dr. Gottlieb will provide further leadership support as Synthetic Biologics moves forward with Phase 2 clinical trials for its irritable bowel syndrome and Clostridium difficile products.

Valeant Pharmaceuticals received FDA approval for its IBS-D drug Xifaxan, according to a Triangle Business Journal report.

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.

More articles on gastroenterology:
Olympus sets aside $450M for expected settlement, EndoChoice launches IPO of 6.25M shares & more – 6 GI/endoscopy company key notes
Lovell Federal Health Care Center opens new GI center
DDW highlights: 3 GI physicians on what excited them most

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.